»
INDUSTRY NEWS
»
accurate quantitation and identifi cation. In addition, a rapid scan function allows rapid sample acquisitions of 20 spectra per second. This enables analysis of reactions occurring within a few seconds, and kinetic studies occurring in less than one second.
The IRTracer-100 features a stable, airtight interferometer that incorporates a built-in automatic dehumidifi er, protecting the unit against moisture and other environmental infl uences.
In addition,
the patented Advanced Dynamic Alignment system, sampling at over 5,000 times per second, works in combination with a smooth-moving mirror to ensure optimum performance, enhanced stability and shorter warm-up times.
Self-diagnostics and monitoring technology allows for quick, easy instrument management. The IRTracer’s validation program enables easy verifi cation of the instrument’s performance. This program complies with U.S., European, Japanese and Chinese pharmacopeias, and with ASTM specifi cations.
Optimized for network applications, new LabSolutions IR Series software off ers intuitive operation, high-level administrative functions, secure data management, and a variety of data manipulation functions. It includes an extensive library of nearly 12,000 spectra as well as a high-performance search function for easier identifi cation of unknown samples. A unique Print Template function allows easy creation and printing of custom reports. In addition, the “Easy Macro” program allows users to eff ortlessly create macros for routine tasks. This improves productivity and allows even novice FTIR users to easily operate the IRTracer-100.
The IRTracer-100 can be customized with a variety of software and hardware options to meet specifi c application requirements. These include contaminant analysis and identifi cation test programs, time- course analysis and 3-D mapping software, an infrared microscope, near/far IR kits, and a variety of ATR accessories.
Cambridge Major Laboratories and AAIPharma Services Announce Merger
Cambridge Major Laboratories, Inc. (“CML”), a global leader in pharmaceutical API development and manufacturing, and AAIPharma Services Corp. (“AAIPharma”), a leading global provider of pharmaceutical analytical testing, product development, and manufacturing services, have announced their intent to merge to form the premier global supplier of integrated CMC services. Financial terms of the merger were not disclosed. The merger is expected to close by the end of October 2013, subject to Hart-Scott-Rodino approval and other closing conditions. “The basis for the merger was to start with the right building blocks - a merger of two equals: two highly respected, market-leading fi rms with proven expertise in API development, analytical chemistry, and fi nished dosage forms,” said Brian Scanlan, CEO & President of CML. “We believe that we have a strong foundation to deliver superior customer-oriented solutions to expedite drug development and commercialization.”
116 | | September/October 2013 - 15TH ANNIVERSARY ISSUE
Scanlan added, “Joining forces to off er a full suite of integrated CMC services delivers meaningful value to customers and the ability to execute with equal strength across API development, analytical services, and fi nished dosage form manufacturing.
The combined
CML and AAIPharma will provide a superior customer experience defi ned by high-quality facilities, best-in-class capabilities, scientifi c expertise, geographic proximity, and eff ective support services that maximize scientifi c and project interaction at each phase.”
”The merger of these two organizations will off er customers a reliable partner that can address the majority of their pharmaceutical development and manufacturing requirements,” stated Patrick Walsh, CEO of AAIPharma Services. “The combined organization will provide comprehensive services that include process chemistry, solid state chemistry, API manufacturing, formulation development, analytical development and testing services, clinical and commercial fi nished dosage form manufacturing (oral solid and sterile), packaging, and stability services, all supported by robust project management.”
Atrium Innovations Acquires 70% of Mucos Pharma CZ, Distributor of Wobenzym® Products in Central and Eastern Europe
Atrium Innovations Inc., a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products, announced that it has acquired 70% of the outstanding shares of Mucos Pharma CZ s.r.o., the exclusive distributor of Wobenzym® products in Central and Eastern Europe.
Over the past few years, the solidly established Mucos CZ has successfully distributed Wobenzym® products primarily in Russia, Czech Republic and Slovakia. This controlling interest in Mucos CZ refl ects the strategic importance of Central and Eastern European markets to Atrium in reference to Wobenzym’s potential and the potential for future cross-selling opportunities particularly in Russia.
The transaction includes an obligation on or before December 31, 2015 to acquire the remaining 30% of Mucos CZ shares allowing for a proper transition. The acquisition price of this transaction is established on a multiple of 4.75 times the last twelve months EBITDA. This transaction of US$15.9 million will be fi nanced with existing credit facilities.
“We have a longstanding relationship with Mucos CZ which has focused solely on selling Wobenzym®,” said Pierre Fitzgibbon, President and CEO of Atrium. “Mucos CZ has been a distributor of Wobenzym® products over the last 20 years. Our intention is to integrate this platform to solidify our Wobenzym® business and to introduce other Atrium products particularly in Russia. The transaction will be accretive to net income immediately following the depletion of the inventory purchased by Mucos CZ prior to the transaction. Consequently, our fourth quarter 2013 gross and EBITDA margins on a consolidated basis will be temporarily negatively impacted.”
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156